ID
15254
Description
A Study of the Safety and Efficacy of Topiramate in the Treatment of Obese, Type 2 Diabetes Patients on a Controlled Diet; ODM derived from: https://clinicaltrials.gov/show/NCT00231530
Lien
https://clinicaltrials.gov/show/NCT00231530
Mots-clés
Versions (1)
- 23/05/2016 23/05/2016 -
Téléchargé le
23 mai 2016
DOI
Pour une demande vous connecter.
Licence
Creative Commons BY 4.0
Modèle Commentaires :
Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.
Groupe Item commentaires pour :
Item commentaires pour :
Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.
Eligibility Obesity NCT00231530
Eligibility Obesity NCT00231530
- StudyEvent: Eligibility
Description
Exclusion Criteria
Alias
- UMLS CUI
- C0680251
Description
hypersensitivity to topiramate
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C1301624
- UMLS CUI [1,2]
- C0076829
- UMLS CUI [1,3]
- C0020517
Description
fasting plasma glucose
Type de données
boolean
Alias
- UMLS CUI [1]
- C0583513
Description
Hba1c
Type de données
boolean
Alias
- UMLS CUI [1]
- C0019018
Description
severe recurrent hypoglycemic episodes
Type de données
boolean
Alias
- UMLS CUI [1,1]
- C0020615
- UMLS CUI [1,2]
- C0205082
- UMLS CUI [1,3]
- C2945760
Description
systemic corticosteroids
Type de données
boolean
Alias
- UMLS CUI [1]
- C2825233
Description
type 1 diabetes
Type de données
boolean
Alias
- UMLS CUI [1]
- C0011854
Description
cardiovascular disease
Type de données
boolean
Alias
- UMLS CUI [1]
- C0007222
- UMLS CUI [2,1]
- C0040128
- UMLS CUI [2,2]
- C0205318
- UMLS CUI [3]
- C0022650
Similar models
Eligibility Obesity NCT00231530
- StudyEvent: Eligibility
C0021641 (UMLS CUI [2])
C1999124 (UMLS CUI [2])
C0076829 (UMLS CUI [1,2])
C0020517 (UMLS CUI [1,3])
C0205082 (UMLS CUI [1,2])
C2945760 (UMLS CUI [1,3])
C0040128 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
C0022650 (UMLS CUI [3])